Acriva Trinova lenses not only manage cataracts, but also provide people with continuous, quality sight in the near, mid, far, and intermediate ranges, the CEO of Dutch-based VSY Biotechnology said Tuesday.
"Thus, Trinova may end dependency on eyeglasses," Ozge Altunbas Goktekin told Anadolu Agency in an exclusive interview, noting that Acriva Trinova is the world's first and only sinusoidal (sine-wave) trifocal intraocular lens.
"Thanks to its special design, Acriva Trinova leads 92 percent of the light into the retina with very high efficiency, making it easier to see even in the darkest places and prevent halos or light distribution," she said. "That's how it provides high vision and comfort in dark places."
Goktekin stated that VSY Biotechnology develops eye technologies on a global scale with its innovative projects, adding:
"Distinguished by its sinusoidal optical structure and seamless vision technology production technique, we've made patent applications worldwide for our Acriva Trinova lenses."
She stressed the vision of her company as "developing the best products with advanced technology through high quality standards in order to enhance people's quality of life."
Goktekin stressed that in line with the company's sustainable growth strategy, VSY products have already been used in around 60 countries -- including Germany, Japan, Brazil, the Philippines, Russia, and South Africa.
"Over the last eight years, 3 million people have been implanted with VSY Biotechnology-branded intraocular lenses through cataract surgery," she said. "And by that, we mean millions of people are able to see perfectly again."
"VSY Biotechnology has come to the aid of those people with lenses designed and made in its own RD department," Goktekin said, adding:
"We keep working with the aim of producing excellent fruits with our innovative RD projects and strong manufacturing capability."
According to the company, VSY Biotechnology’s product range includes intraocular lenses, viscoelastics, and injector and cartridge systems.
